How Effective Is Xofluza for Flu Treatment?
Xofluza (baloxavir marboxil) treats acute uncomplicated influenza in people 5 years and older who have been symptomatic for no more than 48 hours. A single oral dose reduces time to symptom improvement by about 1 day compared to placebo (median 54 hours vs. 80 hours) in clinical trials.[1][2]
Key Clinical Trial Results
Phase 3 trials (CAPSTONE-1 in adolescents/adults, CAPSTONE-2 in children) showed:
- 77-88% of patients tested negative for influenza virus by day 2 post-dose, vs. 48% on placebo.
- Infectious virus was undetectable 24 hours after dosing in most cases, unlike oseltamivir (Tamiflu), which takes longer.[1][3]
FDA approved it in 2018 based on these data, confirming efficacy against influenza A and B strains.[2]
Does It Work Against Resistant Flu Strains?
Xofluza targets the virus's polymerase acidic (PA) endonuclease, reducing resistance risk compared to neuraminidase inhibitors like Tamiflu. Resistance emerged in 0.5-2% of patients in trials, mostly in children or prolonged shedding cases.[1][4] Real-world studies post-approval report sustained effectiveness, including during H1N1 and H3N2 seasons.[3]
How Does Xofluza Compare to Tamiflu?
| Aspect | Xofluza | Tamiflu |
|--------|---------|---------|
| Dosing | Single dose | Twice daily for 5 days |
| Symptom relief speed | ~2.5 days median | ~2.7 days median |
| Virus clearance | Faster (24-48 hours) | Slower (72+ hours) |
| Resistance rate | Lower (~1%) | Higher (up to 10% in some outbreaks) |
Head-to-head trials (MINSTONE-1/2) found Xofluza noninferior or superior for time to alleviation.[1][5] It's preferred for convenience but costs more.
When Might Xofluza Not Work?
- Symptoms >48 hours: Efficacy drops; guidelines recommend against use.[2]
- Severe flu or high-risk patients (e.g., hospitalized): Not studied; IV antivirals preferred.[6]
- Bacterial co-infection: Does not treat; antibiotics needed separately.
- Certain strains: Rare PA mutations confer resistance, seen more in Japan.[4]
Post-marketing data (2023-2024 seasons) shows 90%+ viral reduction rates, with no major efficacy loss.[3]
Who Makes Xofluza and Availability?
Genentech (Roche subsidiary) developed it; Shionogi co-markets in some regions. Available by prescription in the US, priced ~$150-160 per dose (cash; insurance varies).[7] No generic yet—patents expire around 2031 per DrugPatentWatch.com.[8]
[1]: FDA Label - Xofluza (2018)
[2]: CDC Influenza Antiviral Medications (2024)
[3]: NEJM - Baloxavir Marboxil Trial (2018)
[4]: Clinical Infectious Diseases - Resistance Surveillance (2021)
[5]: Lancet Infectious Diseases - MINSTONE Trials (2020)
[6]: IDSA/AVIMA Guidelines (2024)
[7]: GoodRx Pricing Data (2024)
[8]: DrugPatentWatch.com - Xofluza Patents